CAR T Cell Therapy Market is expected to grow with a CAGR of over 46 % in the forecast period

Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.  

Renub Research recent report on CAR T Cell Therapy Market, anticipate that it will grow at with a CAGR of almost 50% over the period of 2018-2028. Over some years, immunotherapy has emerged as one of the most curative ways in the treatment of cancerous tumors among the cancer community which strengthen the power of patient’s immune system to fight these tumors. Immunotherapy; adoptive cell transfer (ACT) for cancer treatment is evolving very rapidly adoptive cell transfer (ACT) which includes collection and usage of patient’s own immune cells in the treatment of their cancer. There are various types of adoptive cell transfer (ACT) are being developed namely; TILs, TCRs, and CARs, of which, CARs- CAR T-cell therapy is the only clinical developed advanced approach used in the treatment of cancer.

Over the several years; the surgery, chemotherapy and radiation therapy are considered to be the best available treatment for cancer. Later, targeted therapies such as trastuzumab (Herceptin®) and imatinib (Gleevec®) like drugs which specifically targets cancer cells are being used in the cancer treatment.

CAR T Cell therapy is a treatment in which a patient’s immune system cell (T cell) are transformed in the clinical laboratory so that the transformed immune system cell will attack cancerous cell in the patient’s body. T cells are usually extracted from the patient’s blood, which is then treated in the laboratory with special receptor known as a chimeric antigen receptor (CAR) and hence, the treatment is termed as CAR T Cell Therapy. The chimeric antigen receptor (CAR) cells tend to act like an antigen on the cancer cells and kill them. Today, with the advancement in medical technology, a large number of CAR T cells are developed in the laboratory and is given to the cancer patients by infusion, which will certainly drive CAR T Cell Therapy Market to grow vigorously in the coming future with increasing cancer cases worldwide and the fuelling demand for better healthcare services from the consumer.

Click here for: Drugs & Pharmaceuticals Research Reports

Recently, the Food and Drug Administration (FDA) has approved two CAR T-cell therapies in 2017 of which one is for the adults with advanced lymphomas and the other for the treatment of children with acute lymphoblastic leukemia (ALL). Nonetheless, the CAR T cells therapy and other forms of ACT are still in its early days and is still being developed and so, the researchers are still cautious about the CAR T cells therapy that will it ever be effective against solid tumors like breast and colorectal cancer.

With increasing research and development, the field of CAR T Cell therapy has reached a tipping point. In the recent years, development in the CAR T Cells and other ACT approaches has pushed immensely, as the researchers are developing a better understanding of how these therapies work with cancer patients and translating that outcome into improvements in how they are developed and tested more efficiently.

In the near future; it is believed that medical science will see a dramatic progress which will push all the boundaries that what a people thought was possible with these cell-transfer based treatments.

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Feb 14th 2019 00:10. Viewed 415 times.

Share on APSense

Comments